MARKET

ITRM

ITRM

Iterum Therapeutics plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.190
0.000
0.00%
Pre Market: 1.190 0 0.00% 09:12 07/06 EDT
OPEN
1.180
PREV CLOSE
1.190
HIGH
1.200
LOW
1.120
VOLUME
91.22K
TURNOVER
--
52 WEEK HIGH
7.65
52 WEEK LOW
1.120
MARKET CAP
21.23M
P/E (TTM)
-0.1763
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ITRM stock price target is 3.333 with a high estimate of 7.00 and a low estimate of 1.000.

EPS

ITRM News

More
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 4d ago
FDX, BYND among premarket gainers
Seeking Alpha - Article · 5d ago
Iterum Therapeutics Announces $5M Registered Direct Offering Priced At-the-Market under Nasdaq Rules; Priced At $1.42/Share
Benzinga · 5d ago
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that it has entered into definiti
GlobeNewswire · 6d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 6d ago
Iterum's sulopenem shows mixed results in pivotal trial
Seeking Alpha - Article · 6d ago
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
GlobeNewswire · 06/29 12:30
NKLA, COTY among premarket gainers
Seeking Alpha - Article · 06/29 12:24

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ITRM

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.
More

Webull offers kinds of Iterum Therapeutics PLC stock information, including NASDAQ:ITRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITRM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITRM stock methods without spending real money on the virtual paper trading platform.